CXCL11 and incontinentia pigmenti: To demonstrate the therapeutic potential of AAV‐BR1, we utilized this brain‐specific capsid mutant to generate a gene therapy vector and were able to ameliorate the severe cerebrovascular pathology in a mouse model of incontinentia pigmenti.